Which of the following adverse effects is associated with D2 occupancy around 50-75%?

Which of the following adverse effects is associated with D2 occupancy around 50-75%?

• A. EPS
• B. Maintenance dosing
• C. Hyperprolactinemia
• D. Clozapine monitoring

Answer: (C)

The main idea is that different dopamine pathways in the brain respond to D2 receptor blockade at different occupancy levels, leading to distinct adverse effects. In the tuberoinfundibular pathway, blocking D2 receptors lifts dopamine’s inhibition of prolactin release from the pituitary, so prolactin levels rise even at moderate levels of occupancy. This is why hyperprolactinemia can occur when D2 occupancy is in the roughly 50–75% range. Extrapyramidal symptoms, on the other hand, are tied more to striatal D2 blockade and tend to appear more prominently once occupancy is higher (often around 70–80% or more). So while EPS can occur with substantial D2 blockade, the pattern of 50–75% occupancy aligns more with prolactin elevation than with motor side effects. Maintenance dosing is not an adverse effect, and clozapine monitoring relates to agranulocytosis risk rather than D2 occupancy-related adverse effects. Hence, hyperprolactinemia fits the occupancy range described.

The main idea is that different dopamine pathways in the brain respond to D2 receptor blockade at different occupancy levels, leading to distinct adverse effects. In the tuberoinfundibular pathway, blocking D2 receptors lifts dopamine’s inhibition of prolactin release from the pituitary, so prolactin levels rise even at moderate levels of occupancy. This is why hyperprolactinemia can occur when D2 occupancy is in the roughly 50–75% range.

Extrapyramidal symptoms, on the other hand, are tied more to striatal D2 blockade and tend to appear more prominently once occupancy is higher (often around 70–80% or more). So while EPS can occur with substantial D2 blockade, the pattern of 50–75% occupancy aligns more with prolactin elevation than with motor side effects.

Maintenance dosing is not an adverse effect, and clozapine monitoring relates to agranulocytosis risk rather than D2 occupancy-related adverse effects. Hence, hyperprolactinemia fits the occupancy range described.